Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research
November 07 2024 - 4:01PM
Business Wire
Officinae Bio’s breakthroughs in AI-enabled
methodologies for nucleic manufacturing to enhance Maravai’s mRNA
manufacturing capabilities within the TriLink BioTechnologies
business
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of
life science reagents and services to researchers and biotech
innovators, announced that it has signed an agreement to acquire
the DNA and RNA business of Officinae Bio. The acquisition is
expected to expand Maravai and TriLink BioTechnologies' ability to
assist customers in developing innovative nucleic acid-based
therapies.
Based in Venice, Italy, Officinae Bio is a privately held
technology company with a proprietary digital platform to support
the biological design of therapeutics. The novel technology enables
rapid prototyping of mRNA candidates to test diverse combinations
of CAP analogs, chemistry modifications, and sequence designs for
client discovery programs. Officinae Bio’s portfolio of technology
and services complements Maravai’s nucleic acid production services
and is expected to provide customers with significant benefits as
they bring new and innovative therapies to patients in need.
“Officinae Bio’s unique approach to sequence design brings a
cutting-edge advantage to our Nucleic Acid Production business,”
said Trey Martin, CEO of Maravai LifeSciences. “Its founder-led,
experienced team maintains a dedicated focus on leveraging AI to
help scale the organization and accelerate innovation. We are
excited to welcome their exceptionally talented team to Maravai to
help drive process and manufacturing innovation forward
together.”
Justin Barbosa, GM and Vice President of TriLink Discovery,
added, “Officinae Bio’s ability to marry leading science with
AI-enabled methodologies provides a one-of-a-kind sequence design
experience for customers. With this acquisition, TriLink solidifies
itself as an expert in mRNA design, customization, and manufacture
with a high-touch digital customer experience.”
Davide De Lucrezia, Chief Executive Officer and co-founder of
Officinae Bio, commented, "I can think of no better team with which
to unite than Maravai and TriLink, whose trusted quality and
leadership supports our dedication to collaboration and continuous
improvement in the life sciences. We remain committed to our
current customers’ success and believe this transaction will
further strengthen our ability to support their needs. This
business combination will also allow us to strengthen our
contribution to the GMP manufacturing of key enzymes needed for
nucleic acid vaccine and therapeutic applications.”
The acquisition is subject to customary closing conditions and
regulatory approvals and is expected to close early in 2025.
About Maravai
Maravai is a leading life sciences company providing critical
products to enable the development of drug therapies, diagnostics
and novel vaccines and to support research on human diseases.
Maravai’s companies are leaders in providing products and services
in the fields of nucleic acid synthesis and biologics safety
testing to many of the world's leading biopharmaceutical, vaccine,
diagnostics and cell and gene therapies companies.
About Officinae Bio
At Officinae Bio we are developing a platform to support the
future of biologically designed therapeutics. By developing
breakthroughs in AI-enabled methodologies for nucleic manufacture
we are supporting pioneering research in Gene-modified Cell
therapy, Gene therapy and RNA therapeutic research.
DNA Platform
Our Vulcanus DNA synthesis platform creates high-precision DNA
libraries with exceptional control over variant representation,
accelerating lead discovery through targeted sequence exploration
with smart mutant libraries.
RNA Platform
Our Mercury RNA platform generates libraries of precisely
engineered UTRs (untranslated regions), optimizing efficacy and
safety through enhanced translation and tissue-specificity
Forward-looking Statements
This press release may contain “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Investors are
cautioned that statements in this press release which are not
strictly historical statements constitute forward-looking
statements, including, without limitation, statements related to
the planned acquisition of the DNA and RNA business of Officinae
Bio and the expected benefits thereof constitute forward-looking
statements identified by words like “plan,” “expect,” “believe,”
“estimate,” “may,” “anticipate,” or “could” and similar
expressions. Such forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, without
limitation, a failure to complete the acquisition due to closing
conditions not being satisfied or otherwise, a failure of Officinae
Bio’s products and services to provide the anticipated benefits,
and competition from other products. These and other risks and
uncertainties are described in greater detail in the “Risk Factors”
section of our most recent Annual Report on Form 10-K, as well as
other reports on file with the U.S. Securities and Exchange
Commission. Actual results may differ materially from those
contemplated by these forward-looking statements, and therefore you
should not rely upon them. These forward-looking statements reflect
our current views and we do not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date hereof except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241107589983/en/
Media Contact: Liz Robinson CG Life trilink@cglife.com
Investor Contact: Deb Hart Maravai LifeSciences + 1 858-988-5917
ir@maravai.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Dec 2023 to Dec 2024